DexCom, Inc. (DXCM)

DexCom's stock (DXCM) has experienced several notable events impacting its price over the past six months. The stock trended down by 8.42% in the past six months and 20.78% in the past year. Key events include strong Q3 2025 revenue and raised full-year guidance, analyst price target adjustments, insider trading activities, a short-seller report alleging issues with the G7 device, an FDA warning letter related to manufacturing processes, and an equity buyback announcement for $750 million worth of its shares.

Demand for DexCom, Inc. products and services is generally not closely tied to economic cycles due to the non-discretionary nature of diabetes management. While there might be some minor fourth-quarter seasonality in internal assumptions, the fundamental demand for DexCom's life-sustaining products is largely consistent throughout the year.

DexCom, Inc. is a medical device company specializing in continuous glucose monitoring (CGM) systems within the Healthcare sector. Its mission is to empower individuals with diabetes through innovative glucose biosensing technology. Key products include Dexcom G6, G7, Share, Real-Time API, ONE, and Stelo, along with Dexcom Care training and support services. DexCom collaborates with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products.

DexCom, Inc. operates in the United States and internationally, focusing on North America and Europe, with expansion into new international markets. The company directly markets its products in countries such as the US, Austria, Canada, Germany, Switzerland, and the UK, and reaches other countries through distributors. The U.S. market accounts for approximately 70% of total revenue, while international revenue is growing rapidly.

DexCom generally maintains a strong brand reputation due to the accuracy of its CGM products. However, the company's reputation has been affected by an FDA warning letter regarding manufacturing processes and a short-seller report alleging issues with the Dexcom G7 device. Despite these challenges, DexCom continues to innovate, with new AI features for its Stelo product.

DexCom, Inc. has significant institutional ownership, with 1605 institutional owners and shareholders holding approximately 79% of the company's shares. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and State Street Corp. Individual investors and insiders own about 21% of the company's shares, and recent corporate insider sentiment has been positive.